Uni-President Backed Meiling Bio Initiates Phase II Trial for Alzheimer's Drug

PharmaEssentia Revenue Surges 83% in First Nine Months

Health Technology · economic_daily · 2026-10-05

PharmaEssentia's year-to-date revenue reached NT$19.73 billion, driven by strong sales of its rare blood cancer drug Ropeg in the U.S. and Japan.

6446

PharmaEssentia September Revenue Doubles, Hits Record High on Strong Drug Demand

Health Technology · economic_daily · 2026-10-05

PharmaEssentia reported a 100% year-over-year revenue surge for September, driven by the global expansion of its rare blood cancer treatment, Ropeg.

6446

Taiwan Biotech Sector Hits Record Market Cap of NT$1.7 Trillion

Health Technology · economic_daily · 2026-10-04

Taiwan's biotech sector reached a record market capitalization of NT$1.77 trillion by the end of September, with 159 listed companies showing strong growth.

TSMC Leads Taiwan Stocks to Record Highs, Nearing 50,000-Point Milestone

Electronic Technology · economic_daily · 2026-10-05

Taiwan's stock market surged over 1,200 points to close at 49,712, driven by TSMC and semiconductor strength, as analysts eye a potential break above 50,000.

2059, 2330, 2368, 2383, 3406, 3491, 6187, 6274, 7750

Taiwan Index Futures Hit 50,000 Milestone; Analysts Eye 55,000 Year-End Target

Electronic Technology · economic_daily · 2026-10-05

Taiwan index futures surged past 50,000 points, fueled by cooling U.S. labor data and strong AI demand, with analysts projecting further gains toward 55,000.

1303, 2308, 2330, 3037, 3105, 3189, 3293, 3665, 4958, 6770, 8046

Taiwan Stocks Reach Record Highs; Analysts Predict Further Upside to 55,000

Electronic Technology · economic_daily · 2026-10-05

Taiwanese equities hit record highs led by TSMC, with analysts remaining bullish on AI-driven growth and projecting potential targets of 53,000 to 55,000.

2330

Taiwan Stocks Surge to New Highs: TSMC and Nanya Lead Market Rally

Electronic Technology · economic_daily · 2026-10-05

Taiwan stocks hit record highs as cooling US rate hike expectations fuel market optimism, with analysts recommending a buy-on-dip strategy for top performers.